<DOC>
	<DOC>NCT02843659</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's syndrome as measured by the change from baseline in ESSDAI at Week 12 between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.</brief_summary>
	<brief_title>Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Subjects diagnosed or classified as having moderate to severe primary Sjögren's Syndrome based on the 2016 ACREULAR Sjögren's Syndrome Classification Criteria for at least 16 weeks prior to screening ESSDAI ≥ 5 including disease activity (any score &gt; 0) in at least one of the following domains: Glandular, Articular, Hematological, Biological, Lymphadenopathy Positive antiSSA/Ro and/or antiSSB/La autoantibody Unstimulated whole saliva secretion &gt; 0.01 ml/min Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug and must not be pregnant or breastfeeding. Male and female subjects must be willing to adhere to protocolmandated highly effective contraception for the duration of the study and for the protocolspecified follow up period. Hormonebased contraceptive methods are not permitted Secondary Sjögren's syndrome or the presence of any other systemic autoimmune disease (eg, RA, SLE, multiple sclerosis, vasculitis) Very severe primary Sjögren's syndrome or severe complications of primary Sjögren's syndrome at the time of the screening visit Active systemic or latent bacterial (including tuberculosis), viral or fungal infection, evidence of current or chronic Hepatitis B or C infection, or HIV infection Any significant concurrent medical condition at the time of screening or baseline visit Use of methotrexate, cyclophosphamide, cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil (MMF) or leflunomide within 12 weeks of screening visit Previous treatment with biologics therapies either marketed or in development within 6 months prior to screening visit Treatment started or an unstable dose of hydroxychloroquine within 8 weeks of screening visit Oral corticosteroids &gt; 10 mg/day within 14 days of dosing (Day 1), corticosteroid therapy ≥ 1 mg/kg during the 4 weeks preceding enrollment, or intravenous, intramuscular or intraarticular corticosteroids within 4 weeks of screening visit Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>